Cargando…

Tolvaptan in the very elderly with acute decompensated heart failure-a therapeutic option worth of consideration

Detalles Bibliográficos
Autor principal:	Ndrepepa, Gjin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kare Publishing 2017
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689053/ https://www.ncbi.nlm.nih.gov/pubmed/28883307 http://dx.doi.org/10.14744/AnatolJCardiol.2017.8033

Ejemplares similares

Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure
por: Niikura, Hiroki, et al.
Publicado: (2017)

Atherosclerosis & ischaemic heart disease: Here to stay or gone tomorrow
por: Ndrepepa, Gjin
Publicado: (2017)

Prognostic Impact of the Early Use of Tolvaptan in Elderly Patients with Acute Decompensated Heart Failure
por: Okada, Tomoaki, et al.
Publicado: (2023)

Is Protein Kinase C Inhibition the Tip of the Iceberg in New Therapeutics for Acutely Decompensated Heart Failure?
por: Pimental, David R., et al.
Publicado: (2017)

Role of ischemia-modified albumin in patients with acute decompensated heart failure
por: Pan, Defeng, et al.
Publicado: (2016)

Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure
por: Ikeda, Shuntaro, et al.
Publicado: (2017)

Renoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status
por: Yamamoto, Tomohiko, et al.
Publicado: (2019)

Tolvaptan should be used very carefully in very elderly patients
por: Kahraman, Fatih, et al.
Publicado: (2018)

Repetitive Acute Hemodynamic Load: Progression From Systolic Decompensation to Cellular/Extracellular Compensation to Diastolic Decompensation
por: Zile, Michael R., et al.
Publicado: (2019)

Oxytocin: A New Therapeutic for Heart Failure?
por: Habecker, Beth A.
Publicado: (2020)

Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)

Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome
por: Aghel, Arash, et al.
Publicado: (2008)

Metabolic Coupling as a Therapeutic Strategy for Heart Failure
por: Young, Martin E.
Publicado: (2019)

A model worth considering?
por: Petsko, Gregory A
Publicado: (2006)

Predictors of in-hospital mortality in elderly patients with heart failure treated with tolvaptan
por: Kobayashi, Masakazu, et al.
Publicado: (2023)

Long-term administration of Tolvaptan to patients with decompensated cirrhosis
por: Kanayama, Kengo, et al.
Publicado: (2020)

Epicardial adipose tissue: An anatomic component of obesity & metabolic syndrome in close proximity to myocardium & coronary arteries
por: Ndrepepa, Gjin
Publicado: (2020)

When failure should be the option
por: Petsko, Gregory A
Publicado: (2010)

US elections: treating the acute-on-chronic decompensation
por: Tsai, Alexander C, et al.
Publicado: (2020)

Early Initiation of Tolvaptan is Associated with Early Discharge in Elderly Heart Failure Patients
por: Kiuchi, Shunsuke, et al.
Publicado: (2021)

Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure
por: Fukuoka, Hidetada, et al.
Publicado: (2020)

Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure
por: Njoroge, Joyce N., et al.
Publicado: (2021)

A new paradigm for the treatment of volume overload in heart failure-combined effect of tolvaptan with furosemide
por: Okamoto, Hiroshi
Publicado: (2013)

Microbial challenge studies—a challenge worth accepting
por: Jefferson, Tom
Publicado: (2005)

Post-tuberculosis sequelae and their socioeconomic consequences: worth investigating
por: Sotgiu, Giovanni, et al.
Publicado: (2021)

Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure
por: Kiuchi, Shunsuke, et al.
Publicado: (2018)

Current Therapeutic Options for Heart Failure in Elderly Patients
por: Guerra, F., et al.
Publicado: (2017)

CFTR Therapeutics Normalize Cerebral Perfusion Deficits in Mouse Models of Heart Failure and Subarachnoid Hemorrhage
por: Lidington, Darcy, et al.
Publicado: (2019)

Internal cardioversion of persistent atrial fibrillation in implantable cardioverter defibrillator patients: the juice is not worth the squeeze
por: Berger, W. R., et al.
Publicado: (2013)

A case report with shock induced by tolvaptan in an elderly patient with congestive heart failure
por: Zhang, Zhi-gang, et al.
Publicado: (2018)

Safety of COVID-19 booster dose: is the juice worth the squeeze?
por: Madhi, Shabir A, et al.
Publicado: (2023)

Coronary No-Reflow after Primary Percutaneous Coronary Intervention—Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy
por: Ndrepepa, Gjin, et al.
Publicado: (2023)

Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure?
por: Mann, Douglas L., et al.
Publicado: (2017)

Direct oral anticoagulant failure in stroke/transient ischaemic attack: neurologic and pharmacokinetic considerations
por: Rose, David Z, et al.
Publicado: (2020)

Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report
por: Kajimoto, Katsuya, et al.
Publicado: (2019)

Heart rate in heart failure with mid-range ejection fraction
por: Yılmaz, Mehmet Birhan
Publicado: (2019)

The Role of Macrophages in Nonischemic Heart Failure
por: Chen, Bijun, et al.
Publicado: (2018)

A Growth Tonic for Heart Failure?
por: Bishopric, Nanette H.
Publicado: (2016)

Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2021)

Tolvaptan: A Novel Diuretic in Heart Failure Management
por: Zulkifli Amin, Hilman, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5b0b4dqgmk478d18qn7kf6ffid